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Thoracic Duct Drainage in Or'gan Transplantation: 
Will It Permit Better Immunosuppression? 
T. E. Starzl, L J. Koep, R. Weillll, C. G. Halgrimson. and J. J. Franks . 
BETTER clinical immunosuppression may. 
well depend on some completely new 
approach. such as the exploitation of suppres-
sor cells in some as yet undefined way. There 
is also the straightforward possibility of better 
drugs. as exemplified by the exciting reports 
by CaIne on the fungus extract, cyclosporin. 
A third possibility, which is the subject of this 
article, is more effective use of an older 
procedure, thoracic-duct drainage. 
HISTORICAL NOTES 
The profoundly suppressive effect of this 
procedure on cell-mediated immunity, anti-
body responses, and homograft rejection were 
established in rats by Gowans:-3 Woodruff 
soon demonstrated that synergism of tho-
racic-duct drainage with another Iymphoid-
depleting modality, antilymphocyte serum.4 
In 1964, Franksson of Stockholm introduced 
thoracic-duct drainage into clinical transplan-
tation, combining it with azathioprine and 
steroids. S In all this pioneering work, 
lymphoid depletion was carried out in 
advance of transplantation, thus conditioning 
the host by' removing small lymphocytes, 
which Gowans had shown easily and quickly 
crossed the interface between blood and 
lymph.! 
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I n the 1960s, further important clinical 
trials were made, the largest being in Sweden 
under Franksson,6.7 in Boston by Murray and 
Tilney,8-IO and in Galveston by Fish and 
Sarles. II .ll Except for Franksson, these early 
investigators emphasized pretreatment. In 
contrast, Franksson provided little pretreat-
ment and maintained the fistulas as long as 
possible after arrival of the renal homografts. 
Although the details varied, all of the forego-
ing reports concluded that there was benefit 
from thoracic-duct fistula. Since the claims 
were unequivocal, it was surprising that the 
trials were not taken up elsewhere and that 
they were even abandoned in the originating 
institutions. Reasons for nonacceptance of the 
procedure included nonreIiability, expense, 
and annoyance. In half or more of the cases in 
Sweden and Boston, the fistulas could not be 
established or else failed within a few days. In 
some of the trials, failure to reinfuse the 
lymph after cell removal caused plasma 
volume problems . 
Another reason for discouragement may 
have been negative clinical reports from 
France,13 ltaly,!4 Brazil, IS and Japan:6 The 
latter studies implied or openly concluded 
that there was no justification for further use 
of thoracic-duct fistula in human transplanta-
tion. However, the volumes and duration of 
lymph drainage in these studies were gener-
ally suboptimal. 
The only workers to continue were those at 
Vanderbilt University in Nashville, Tenn. 
Walker'7 and Johnson'8 and their colleagues 
published striking reports in 1977 about 50 
cadaveric kidney. recipients who were consid-
ered medically and immunologically high risk 
and who were given badly matched kidneys. 
Thoracic-duct drainage was started about a 
month in advance of transplantation and 
continued for variable times afterwards. The 
graft survival 2-5 years later was almost 75%, 
nearly twice as good as in a control group. 
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THORACIC DUCT DRAINAGE 
An influential paper, not concerned with 
transplantation, was recently published by 
Machleder and Paulus of Los Angeles, using 
human thoracic-duct drainage as the sole 
treatment of autoimmune diseases, such as 
rheumatoid arthritis and scleroderma. '9 This 
superb study defined in humans the time 
curves for suppression of humoral and cell-
mediated immunity originally described over 
a 5-day period in rats by McGregor and 
Gowans.2 The full effect in humans was not 
achieved until after 30 days. 
LIVER TRANSPLANTATION 
Machleder's article was given orally in 
Louisville, Ky., at the Society of University 
Surgeons in early February 1978. Within a 
few weeks, we faced seemingly insurmount-
able management problems with one of our 
liver recipients who had deteriorating liver 
function despite treatment with azathioprine 
and high doses of prednisone. At the same 
time, there was a massive wound infection 
and breakdown of his thoracoabdominal inci-
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sion. Thoracic-duct fistula was started 1 
month after transplantation and maintained 
for 71 days (Fig. 1). Prednisone was reduced 
from a high level to 10 mg/day. Liver func-
tion slowly returned to normal. Although the 
patient required respirator support for several 
weeks, he recovered fully, requiring only a 
final upward adjustment of maintenance 
steroids 2 months after discontinuance of the 
thoracic-duct fistula. A second liver patient 
was treated with thoracic-duct fistula, start-
ing 13 days after transplantation, under worse 
circumstances, including the presence of 
enteric fistulas. She also recovered and has 
also returned home. 
We have performed thoracic-duct fistula 
on 9 liver recipients (Table 1), the two 
described above after a delay of 2-4 weeks, 
and 7 more at the time of liver transplanta-
tion. Seven of the 9 patients are alive with 
followups of 11/2-61/2 months. It has been 
impossible for us to achieve such consistency 
of results in the past. One of the two deaths 
was due to massive infection after a bowel 
LTD I 
32 yeor old d 
TIME IN DAYS 
~;o t. Us .. 0' thoraclc·duet fistula 4 weeks after orthotopic liver Iran. plantation for chronic .ggrelllye hepatitis. The 
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Table 1. Uver Recipient. qraet~ With Thoracic Duct Flatu .. 
Alive D .. d FOllow·Up (Month,) 
7 At tranaplantation 
2 Delayed 
5 
2 
2 (Aft.r 16 Ind 42 days) 
o 
1l;K1l;KOKO~K4~ 
elnd U~ 
perforation. Liver function was always 
normal. The other patient's homograft did 
not function well and developed multiple 
areas of necrosis after transplantation from a 
B donor to an A recipient. There may have 
been an element of hyperacute rejection 
because of the blood group violation.20 
wac 
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(billion,) 
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BILlRUUI 
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(mg/dGy) 
PREDNISONE 
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When thoracic-duct fistu1'a was performed 
at the time of liver transplantation, the lymph 
drainage tended to be sluggish at first, reach-
ing, in individual adults, a relatively stable 
level within a few days. These volumes varied 
from 3 (Fig. 2) to 7 or 8 liters (Fig. 1). It was 
interesting in these cases that the number of 
24 
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THORACIC DUCT DRAINAGE 
lymphocytes removed declined at first but 
returned later in large numbers (Figs. I 
and 2) as if there were a lymphocyte-prolifer-
ative response to the homograft antigens. The 
percentage of T lymphocytes collected in the 
thoracic-duct lymph tended to remain high 
throughout the treatment period (Figs. 3 
and 4). In all hepatic recipients (Figs. 1 
and 2) as well as in renal recipients (Figs. 3 
and 4) with thoracic-duct drainage, a remark-
able reduction occurred in the serum concen-
tration of the different immunoglobulin 
classes. This finding has important implica-
wac 
(mm!) 
TOTAL 
LYMPHOCYTES REMOVED 
(billions) 
LYMPH REMOVED 
(mI124h,) 
BUN 
(mg ~F 
AZATHIOPRINE 
(rng/doy) 
PREDNISONE 
(mg/day) 
o 4 8 12 
tions, to be discussed later, in carrying out 
renal transplantation in the face of antidonor 
cytotoxic antibodies. 
In all but 1 of the 7 liver recipients still 
surviving, it was possible to reduce the predni-
sone doses to relatively low levels, below 5 
mg/kg (Figs. I and 2). The fistulas were then 
discontinued after 1-2V2 months. The aza-
thioprine and steroid management (with or 
without antithymocyte globulin-A TG) were 
used as we have practiced in the past, ,,;th 
emphasis on reducing prednisone doses as 
rapidly as possible. 
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drelnege, even though the eel""r .. lymph II ,elnfuled. 
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KTD 5 
53 yeor old d 
TIME IN DAYS 
Fill. 4. Mod"ately .. v"e renal homograft rejection that occurred In ,plte of thoraelc-duct drainage and depended on 
Inten,fflcallon of prednl,one therapy lor reve,.al. Nole that the totallymphocyt .. removed per day w .. IIreater at the end 
01 thorec\c-ducl drainage than et the beginning. 
MANAGEMENT OF 
THORACIC-DUCT FISTULAS 
Since thoracic-duct drainage has had a 
high failure rate, some important details are 
worth mentioning. In our center. the inci-
dence of successful thoracic·duct drainage 
has been 94%. The thoracic duct is cannu-
lated in the left neck. Into the duct is inserted 
a Swan-Ganz catheter. after cutting off the 
balloon. Valves in the duct are passed by the 
judicious use of metal probes, and the cathe-
ter is placed into the superior mediastinum. 
Heparinized saline (1000 U heparin in 500 ml 
saline) is infused at about 20 ml/hr. Provid-
ing the infusion is continuous, this small 
amount of heparin is enough to prevent clot-
ting of the lymph at the catheter tip. Further-
more, additional anticoagulant has not been 
necessary in the transfer packs.' After cen-
trifugation, the cell-free supernatant in the 
-Transfer packs of 400-ml capacity were kindly 
donated by thc FenwalL Corporation. Deerfield. III., for 
these pilot studies. Special transfer packs have been 
designed for thoracic-duct drainage and wiJI be commer-
cially available by about November I, 1978 for approxi-
mately $4.50 per pack. 
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THORACIC DUCT DRAINAGE 
collecting bag is passed by a closed system 
into a second bag. About 99% of the removed 
cells are small lymphocytes. A day's collec-
tion of cell-free lymph is reinfused intrave-
nously throughout the next day. 
In our experience and that of the Vander-
bilt surgeons,18 a narrow spectrum anti-
staphylococcal antibiotic must be given to 
prevent staphylococcal bacteremia. When a 
decision is made to discontinue the thoracic-
duct fistula, the collection bags are elevated 
from their normal position near the floor, to 
above body level, and the heparin infusion is 
stopped. When drainage stops, the catheter is 
gently but firmly pulled out. 
RENAL TRANSPLANTATION 
The same general approach of thoracic-
duct fistula at the time of transplantation was 
carried out in 20 renal recipients treated from 
2 to 5 months ago. Three received poorly 
matched parental kidneys, and the other 17 
received poorly matched cadaveric trans-
plants. Sixteen of the 20 organs are function-
ing at 2-5 months, including 3 of the 3 related 
grafts and 13 of the 17 cadaveric kidneys. 
In Table 2 are given data on the 17 cadav-
eric cases, which were compared with the last 
50 consecutive cadaveric transplantations 
performed at our center under standard 
azathioprine-prednisone or azathioprine-
prednisone-ATG therapy. The extent of the 
histoincompatibility was extreme in both 
groups, with an average of almost 3 mis-
matches. The percentage of patients treated 
with A TG was about 60% in both groups. 
The quantities of lymph and the numbers 
of lymphocytes removed during the first 3 
weeks of thoracic duct drainage are summa-
rized in Table 3. The volumes were large, 
averaging 3.4 liters/day. 
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At 2 months, ) 3 of the 17 cadaveric kid-
neys were (and for that matter still are) 
functioning (Table 4). There were no deaths 
within the first 2 months, and the creatinine 
was below 2 mg/IOO ml in )0 of the 13 
remaining kidneys. The prednisone doses in 
the first 2 months were not significantly 
different than in the retrospective controls 
(Table 5), nor was the incidence of rejection 
(Table 6), but the percentage of functioning 
kidneys was higher (77% versus 60%; Ta-
ble 4). Perhaps something of the late fate of 
such patients may be inferred from the small 
number of late graft losses in the earlier. 
studies from Sweden6.7 and the recent ones 
from Vanderbilt. 17.18 As mentioned earlier, 
the graft survival rate at 2-5 years in the 
Vanderbilt series was 75%. 
In Fig. 3 is shown the course of a cadaveric 
kidney recipient who had no rejection. 
Thoracic-duct drainage was discontinued 
after a month and the patient discharged on 
25 mg of prednisone. The drainage volume 
was about 3000 ml lymph/day. Throughout 
the drainage, T and other lymphocytes 
persisted in the lymph. There was striking 
depression of immunoglobulins. 
The renal recipient whose course is shown 
in Fig. 4 had a severe but reversible rejection 
Consequently, his high volume fistula (whicl 
produced about 6 liters/day) was left for: 
months. The quantities of lymphocytes an, 
their T-cell components did not diminish. 
What has happened to the four patienl 
who rejected their cadaveric kidneys? Or 
has been successfully retransplanted; tv. 
others, who still have their thoracic-du 
fistulas in, are awaiting retransplantatio 
and the family of a fourth patient request, 
discontinuation of the thoracic-duct fistl 
and treatment with dialysis. When a fi 
Table 2. C8daveric Kidney Tranaplent8l1on 
No. ,.. Anligen Antigen No. of No. of Patie 
e .. e, IVears) Mala- Mismatches Retransplant.tiona GivenATt 
llIoracic·duct 
fistula 17 34.4 '* 13.8 (SO) 1.0 =* 0.7 (SO) 2.7 '* 0.7 (SO) 3 (18%) 10(61" 
Controls" 50 42.1 '* 11.8 (SO) 0.8 '* 1.0 (SO) 2.8 '* 1.0 (SO) 18 (36") 30 (60')( 
"Consecutive cases: November 1976--June 1978 . 
'- .. 
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Tabla 3. 11lOraclc-Duct Dralna"a In , 7 Cadaveric Kldnay Raclpiants 
Duration Days Total Volume' TOIII Lymphocyte. Remove<!' 
(Range) Meln Range 
23 Days- > 2 months 38-1 Q6 Liter. 72.4 :to 20 Liters 16.8::1:: 55.0 x 10' 
'Infilsl3 weeks. 
. '. 
Teble 4. Rasuf1sln First 2 Months Aftar Cadeveric Ranal Transplantation 
_ :,. .. , Kidneys 
Funclioning 
., a;2 Monlhs 
Serum Creatinine 
in Kidneys 
Funclioning 
112 Monlhs .•..• 
>2mg/100ml <2mg/100ml 
Mean 
25.9::1:: 9.8 x 10' 
Palients 
Dead al 
2 Monlhs 
17 ThOracic-duct fistula .• ' 13 (77%)' 3 10 0 
' ..... 
50 Controls :<30180%1 5 25 5f ___________ -"-________________ --.:--_..,."... __ ,.----, __ ".. t" 
• Of the 4 patients who lost the:ir grafts. 1 had. stlctessful cadaver. retransplantation 4 we~ks '-lifter"the originil'lrans·ptant . -'. 
with continuing thoracic·duct drainageK~ 
t Two of these five patients died wit~ormal renal fu nction. 
~DC 
kidney-fails with this approa&h of thoracic- or longer of thoracic-duct drainage, 3 of 5 
duct fistula and simultaneous ttUnspl~ntationI kidneys were successfully transplanted across 
the initial period of thoracic-duct drainage in positive cytotoxic crossmatches with function 
a failed attempt can'be viewed as pretreat" of these 3 kidneys more than 2 years. If this 
ment for the second kidneyI~ .apparently obs~rvation were reproduced, the large reser-
with little risk as reflected bYlpt zero mortal- voir of untran~ableK renal patients th~t 
ity. With the unpredictabilitv~9qgan supply, have corrwtt5Plague every maJo er would 
the practicality of this strategy '.s ~vident in be¥< accessible to treatment. Bee use 01' ....... 
cadaveric transplantation. The early work of J.l(e very drastic reductions in serum immuno-
Dumont et al.21 and Singh elal.22 'have indi- //globulins caused by thoracic-duct drainage, 
cated that thoracic-duct drai~Kage at the ti the possibility has seemed logical. 
of skin or renal homotransl?lanta~jon i as We have carried out transplantation'in two 
effective as prior treatment, b?Jt this c1ini ally patients whose sera killed 100% of cells in our 
important point of timing m~st be. r:e test panel as well as the lymphocytes. of their 
ined in the experimental labo~toryK ; donors. The first recipient was given a kidney 
RENAL TRANSPLANTATloR AGAINS 
CYTOTOXIC ANTIBODIES 
Even now, in special cases, pretreat nt 
. may be advisable or even obliiatory. A sign 
observation was made by Niblack et al. of 
Vanderbilt23 who reported thit after a~ month 
after 4 weeks of thoracic-duct drainage. The 
organ did not undergo hyperacute rejection 
but functioned poorly and had to be removed 
19 days later because it was consuming plate-
lets to an alarming degree. In the meanwhile, 
7 weeks of thoracic-duct fistula, 
was placed and, this time 
Tabla 6. Ma.n Prednisone Dose IMg/Day; at Weekly Intervels During First I Weak' After Renal Transplantation 
With PasSI"e of Tin'ili. Patients With Lost Kidnays Were Dropped From Analysis' 
17 Thoracic·duct fistulas 
50 Controls 
\:" 117 :k:'34 
111>-
1PU~ 21 
_ , 14-7) 
• Number of cases at each time is in p4fenthes8s . 
• r>' ~K 
Time in Weeks 
2 3 
93", 55 
(17) 
89::1:: 42 
(44) 
74 ",53 
115) 
77::1:: 42 
142) 
6 
54::1:: 47 
(13) 
60",44 
133) 
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THORACIC DUCT DRAINAGE 
Table II. "ejections In First 2 Month. After C.deverlc 
"anel Trensplanbluon 
17 Thoracic-duct 
fistula. 
50 Controls 
No 
Rejection 
6(35%' 
19 (38%' 
0 ... 
Rejection 
7 (41%1 
24(48%' 
More 
Than 
0 ... 
Rejection 
4 (24%' 
7 (14%' 
organ functioned adequately. A second 
patient was given a kidney across a positive 
crossmatch, and the organ has functioned 
perfectly. Although these follow-ups are of 
short duration, they are highly encouraging, 
since the predictable disaster of hyperacute 
rejection under these conditions has been 
avoided. 
PANCREAS TRANSPLANTATION 
Finally, a partial pancreas (neck, body, and 
tail) and kidney transplantation was per-
PF,lEDNISONE 
(mQ/doyl 
IMURAN 
ImQ/doy) 100 
283 
formed in an adult with thoracic-duct drain-
age. Both first organs were rejected, as was a 
second kidney placed 13 days after institution 
of thoracic-duct drainage. However, a second 
pancreas transplanted across a strongly posi-
tive crossmatch after 17 days of thoracic-duct 
drainage has functioned perfectly for more 
than 2 months despite very minimal immuno-
suppression, consisting now of 10 mg/day of 
prednisone and little (12.5 mg/day) or no 
Imuran (Fig. 5). The patient, whose daily 
insulin requirements were 40--60 U now 
requires no replacement therapy. 
SUMMARY 
It is possible that thoracic-duct drainage. a 
major but neglected immunosuppressive ad-
junct, can have an important impact on organ 
transplantation. If thoracic-duct drainage is 
started at the time of transplantation. the 
J.D. KIDNEY AND PANCREAS TRANSPLANTATION 
WITH THORACIC DUCT DRAINAGE 
1RM4-------~i--------------------------------------
SERUM AMYLASE 
IDye Units 'lI.) 
FASTING BLOOD SUGAR 
(mQ'lI.) 
INSULIN 
(1\ units/day) 
200 
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100 
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1001 _____ ~ ______ ~~~~_t~~~~~~~~ 50-+ 
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I Fig. 5. Cour.e of a patient who received two kidney and two pancreas tran.plants. Tha first two kid nays and the first 
I pancra .. were rejected. The patient had a strongly positive cytotoxiC cro .. match agaln.t lymphocyte. of the .econd 
pancreatic donor. but in Iplte of thll. the organ hal functioned perfectly. Note the c .... tlon of Inlulln requlramentl from 
day 18 onward. 
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practicality of its use in cadaveric> cases is 
greatly enhanced. With kidney transplanta-
tion, the penalty of not having pretreatment 
for the first organ is compensated by the 
automatic presence of pretreatment if rejec-
tion is not controlled and retransplantation 
becomes necessary. Thcr advantage of adding 
thoracic-duct drainage to conventional immu-
nosuppression may greatly enhance the 
expectations for the transplantation of extra-
STARZl ET Al. 
renal organs, such as the liver, pancreas, 
heart, and lung. There is evidence that 
pretreatment with thoracic-duct drainage of 
patients with cytotoxic antibodies may permit 
successful renal transplantation under these 
otherwise essentially hopeless conditions. Ex-
ploration of the neglected but potentially 
valuable tool of thoracic-duct drainage seems 
to us to be highly justified in other centers. 
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